Daiichi Wins Enforcement Of $550M Ranbaxy Award In India

By Caroline Simson (January 31, 2018, 6:09 PM EST) -- Daiichi Sankyo Co. Ltd. on Wednesday won enforcement in India of a $550 million arbitral award against the former owners of Ranbaxy Laboratories Ltd., which had concealed information about fraudulent practices and ongoing investigations during negotiation of a $4.6 billion deal in which Daiichi acquired Ranbaxy shares.

The Japanese drugmaker won the award in 2016 from a Singapore arbitral tribunal, which concluded that former Ranbaxy CEO Malvinder Singh and certain business associates had fraudulently misled Daiichi about the severity of certain investigations being conducted by U.S. regulatory agencies over an alleged scheme in which Ranbaxy falsified data to more quickly obtain...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!